Nxera Pharma and Holling: A Strategic Partnership for Insomnia Treatment in Taiwan

Nxera Pharma Co., Ltd. (TSE: 4565) has entered into a licensing, supply, and commercialization agreement with Holling Bio-Pharma Corp. for the treatment of insomnia in Taiwan using daridorexant, a novel dual orexin receptor antagonist. This strategic partnership aligns with Nxera's mission to lead the next era of medicine and accelerate the development of life-changing medicines for patients in Japan and globally.



Daridorexant, marketed as QUVIVIQ™ in Japan, has shown promising results in clinical trials and was approved by the Ministry of Health, Labour and Welfare of Japan in September 2024. The drug is an oral treatment for adult patients with insomnia, targeting the wake-promoting neuropeptides orexin (OX1R and OX2R) to inhibit excessive wakefulness and facilitate the transition to sleep.

Under the agreement, Nxera Pharma will be responsible for the supply of drug product, while Holling will handle regulatory, commercial, and distribution activities. Holling expects to file a New Chemical Entity (NCE) to the Taiwan Food and Drug Administration (FDA) in mid-2025, with an expected launch in mid-2026 if approved. Nxera Pharma will receive an upfront payment, near-term regulatory and sales milestones, royalties on net sales from Holling, and revenue on the supply of drug product to Holling.

This partnership enables Nxera Pharma to expand its reach in the APAC region, leveraging Holling's expertise as a leading commercial distributor in Taiwan. By working together, Nxera and Holling aim to bring daridorexant to the growing population of patients suffering from insomnia in Taiwan, improving their quality of life and overall well-being.



In conclusion, the strategic partnership between Nxera Pharma and Holling Bio-Pharma Corp. for the commercialization of daridorexant in Taiwan represents a significant step forward in Nxera's mission to lead the next era of medicine. By combining Nxera's innovative drug development capabilities with Holling's commercial expertise, the two companies aim to bring life-changing treatments to patients in need, ultimately improving the health and well-being of individuals across the APAC region.